Hikma Pharmaceuticals Plc Total Voting Rights (4251B)

TIDMHIK

RNS Number : 4251B

Hikma Pharmaceuticals Plc

03 April 2017

Hikma Pharmaceuticals PLC

Total Voting Rights and Capital

LONDON, 3 April 2017, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 239,978,804 ordinary shares with voting rights. There are nil shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FCA's Disclosure and Transparency Rules.

- ENDS -

Enquiries

 
 Hikma Pharmaceuticals PLC 
 Peter Speirs 
  Company Secretary           +44 20 7399 2760

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVREALLDESNXEFF

(END) Dow Jones Newswires

April 03, 2017 10:59 ET (14:59 GMT)

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Oct 2024 to Nov 2024